CDK4 and esophageal squamous cell carcinoma: These findings provided potential candidate biomarkers for PI3Kα inhibitors in treating ESCC patients and proposed rationale to improve the efficacy of PI3Kα inhibitors by simultaneously targeting CDK4/6.